Colchicine: An Ancient Drug with Modern Uses

References

1. Nerlekar N, Beale A, Harper RW. Colchicine—a short history of an ancient drug. Med J Aust. 2014 Dec 11;201(11):687–688.
2. Hartung EF. History of the use of colchicum and related medicaments in gout; with suggestions for further research. Ann Rheum Dis. 1954 Sep;13(3):190–200.
3. Roddy E, Mallen CD, Doherty M. Gout. BMJ. 2013 Oct 1;347:f5648.
4. Roubille F, Kritikou E, Busseuil D, Barrere-Lemaire S, Tardif JC. Colchicine: An old wine in a new bottle? Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):14–23.
5. Leung YY, Yao Hui LL, Kraus VB. Colchicine—Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015 Dec;45(3):341–350.
6. Sardana K, Sinha S, Sachdeva S. Colchicine in dermatology: Rediscovering an old drug with novel uses. Indian Dermatol Online J. 2020 Sep 19;11(5):693–700.
7. Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: A rationale for use of low-dose colchicine. Br J Pharmacol. 2008 Mar;153(6):1288–1295.
8. COLCRYS. accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022352s017lbl.pdf.
9. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447–1461.
10. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29–42.
11. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr;62(4):1060–1068.
12. Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017 Sep;70(3):422–439.
13. Ozkaya N, Yalcinkaya F. Colchicine treatment in children with familial Mediterranean fever. Clin Rheumatol. 2003 Oct;22(4–5):314–317.
14. Manenti L, Maggiore U, Fiaccadori E, et al. Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study. PLoS One. 2021 Mar 24;16(3):e0248276.
15. Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021 Feb;7(1):e001455.
16. Tardif JC, Bouabdallaoui N, L’Allier PL, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19 [preprint]. medRxiv2021. 2021 Jan 27.
17. Robinson J. RECOVERY trial halts recruitment to colchicine arm because of a lack of ‘convincing’ evidence. Pharm J. 2021 Mar 8.
18. clinicaltrials.gov. https://clinicaltrials.gov/ct2/results?cond=colchicine+covid&term=&cntry=&state=&city=&dist=.
19. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013 Oct 17;369(16):1522–1528.
20. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019 Dec 26;381(26):2497–2505.
21. Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: The Australian COPS randomized clinical trial. Circulation. 2020 Nov 17;142(20):1890–1900.
22. Das SK, Mishra K, Ramakrishnan S, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2002 Apr;10(4):247–252.
23. Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Ann Rheum Dis. 2011 Apr;70(4):571–575.
24. Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol. 1985 Ag;13(2 Pt 1):193–200.
25. Robinson KP, Chan JJ. Colchicine in dermatology: A review. Australas J Dermatol. 2018 Nov;59(4):278–285.
26. Sais G, Vidaller A, Jucglà A, et al. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol. 1995 Dec;131(12):1399–1402.
27. Sullivan TP, King LE Jr., Boyd AS. Colchicine in dermatology. J Am Acad Dermatol. 1998 Dec;39(6):993–999.
28. Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i4–i11.
29. Fernandez C, Figarella-Branger D, Alla P, et al. Colchicine myopathy: A vacuolar myopathy with selective type I muscle fiber involvement. An immunohistochemical and electron microscopic study of two cases. Acta Neuropathol. 2002 Feb;103(2):100–106.
30. Gunter SJ, Kesselheim AS, Rome BN. Market exclusivity and changes in competition and prices associated with the US Food and Drug Administration Unapproved Drug Initiative. JAMA Intern Med. 2021 May 17;3211989.
31. Kesselheim AS, Solomon DH. Incentives for drug development—The curious case of colchicine. N Engl J Med. 2010 Jun 3;362(22):2045–2047.
32. Kesselheim AS, Franklin JM, Kim SC, et al. Reductions in use of colchicine after FDA enforcement of market exclusivity in a commercially insured population. J Gen Intern Med. 2015 Nov;30(11):1633–1638.
33. Gallegos A. Court allows generic colchicine to enter market 2015. Rheumatology News. 2015 Jan 28.
34. McCormick N, Wallace ZS, Yokose C, et al. Prolonged increases in public-payer spending and prices after unapproved drug initiative approval of colchicine. JAMA Intern Med. 2021 Feb 1;181(2):284–287.
35. Termination of the Food and Drug Administration’s unapproved drugs initiative; request for information regarding drugs potentially generally recognized as safe and effective. Department of Health and Human Services. hhs.gov. 2020 Nov 20.